Monte Rosa Therapeutics, Inc. GLUE Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $4.21M+51.4% | $2.78M-78.2% | $12.77M-45.0% | $23.19M-72.7% | $84.93M+40.0% | ||
| $44.07M+5.0% | $41.98M+14.5% | $36.68M+19.7% | $30.65M-4.8% | $32.19M-17.2% | ||
| $10.18M-3.3% | $10.52M+16.0% | $9.07M+12.0% | $8.1M-7.0% | $8.7M-0.8% | ||
| $54.24M+3.3% | $52.5M+14.8% | $45.74M+18.1% | $38.75M-5.2% | $40.89M-14.2% | ||
| -$50.03M-0.6% | -$49.72M-50.8% | -$32.98M-112% | -$15.55M-135% | $44.04M— | ||
| -1,188.5%+599pp | -1,787.7%-1,529pp | -258.3%-191pp | -67.1%-119pp | 51.9%— | ||
| $5.59M+51.6% | $3.69M+34.3% | $2.75M-10.5% | $3.07M-10.8% | $3.44M+32.5% | ||
| $5.58M+53.4% | $3.64M+33.9% | $2.72M-39.1% | $4.46M+21.4% | $3.67M+41.4% | ||
| -$44.45M+3.5% | -$46.08M-52.3% | -$30.26M-173% | -$11.1M-123% | $47.71M— | ||
| $52K— | $0+100% | -$3.18M-365% | $1.2M+45.9% | $822K-62.0% | ||
| -$44.5M+3.5% | -$46.11M-70.3% | -$27.08M-120% | -$12.3M-126% | $46.89M— | ||
| -1,057.1%+601pp | -1,658%-1,446pp | -212.1%-159pp | -53%-108pp | 55.2%— | ||
| -$48.01M-0.8% | -$47.63M-54.2% | -$30.88M-130% | -$13.43M-129% | $46.08M— | ||
| -1,140.3%+572pp | -1,712.6%-1,471pp | -241.9%-184pp | -57.9%-112pp | 54.3%— | ||
| -$50.03M-0.6% | -$49.72M-50.8% | -$32.98M-112% | -$15.55M-135% | $44.04M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s revenue?
- Monte Rosa Therapeutics, Inc. (GLUE) generated $43.0M in revenue over the trailing twelve months, down 73.1% year over year.
- Is Monte Rosa Therapeutics, Inc. profitable?
- Monte Rosa Therapeutics, Inc. is not currently profitable: it reported a net loss of $130.0M over the trailing twelve months, a -302.6% net margin.
- What is Monte Rosa Therapeutics, Inc.'s earnings per share?
- Monte Rosa Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.48.
- Where does Monte Rosa Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
